secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001213900-23-062628
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC signs binding term sheet for China license of MDD/ADHD drugs; up to $20M in fees plus royalties
--------------------------------------------------------------------------------

- Binding term sheet with Xinnovation Therapeutics for exclusive license of ABV-1504 (MDD) and ABV-1505 (ADHD) in mainland China.
- Potential aggregate income of $20M in licensing fees plus royalties of 5-12% of net sales.
- Final definitive agreement expected within one year; subject to due diligence, regulatory approvals, board approval.
- Xinnovation will bear all costs for clinical trials and product registration in China.
- ABVC states royalty revenue could reach ~$50M annually and ~$1B over patent life if expected sales achieved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023062628/0001213900-23-062628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023062628/ea182689-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-062628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer